SAGE-217 in major depressive disorder: A multicenter, randomized, double-blind, Phase 2 placebo-controlled trial

Gunduz-Bruce, H; Silber, C; Rothschild, A; Riesenberg, R; Sankoh, A; Li, H; Li, E; Zorumski, C; Rubinow, D; Paul, S; Jonas, J; Doherty, J; Kanes, S

EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019; 29 (): S59